{Reference Type}: Journal Article
{Title}: Antithyroid drug therapy in pregnancy: a review of guideline recommendations.
{Author}: Khan I;Okosieme O;Lazarus J;
{Journal}: Expert Rev Endocrinol Metab
{Volume}: 12
{Issue}: 4
{Year}: 07 2017
暂无{DOI}: 10.1080/17446651.2017.1338944
{Abstract}: The antithyroid drugs, Carbimazole, Methimazole, and Propylthiouracil remain the mainstay of Graves' disease management in pregnancy. A series of Clinical Practice Guidelines aimed at optimising fetal and maternal outcomes in women with Graves' disease have been published in recent years. Areas covered: This review examines existing guideline recommendations on antithyroid drug management of Graves' disease in pregnancy. Expert commentary: Recent guidelines have been shaped by expanding knowledge of the adverse effect profiles of antithyroid drugs on the developing fetus. A core management strategy is to limit fetal exposure to excess thyroid hormones and to curtail adverse drug effects through effective preconception and peri-conception management. Propylthiouracil is the recommended treatment in the first trimester of pregnancy but there is uncertainty regarding antithyroid drug choices in women who continue to require treatment in later pregnancy. Further studies are needed to fully evaluate the risks of congenital anomalies following intrauterine thionamide exposure.